Contract wins round-up: LO-Q, Motive TV, Plexus ...

Also included in this round-up: ValiRx, Eckoh

Lo-Q has announced its second contract win of the week, as an unnamed major US theme park operator has signed up to use the firm's virtual queueing system at two sites in the US. Revenue associated with the agreement is expected to scale gradually, over time. In addition, the deal grants that Lo-Q's virtual queuing systems may be extended into additional theme and water parks within the USA and globally.

Motive Television keeps pace with Lo-Q, announcing its second contract award of the week as well. Mediaset, the Italian film and television giant, has renewed Motive Television's contract for another year, following the launch this week of version 3.0 of the London firm's patented broadcast video-on-demand solution.

Completing a hat-trick of companies that announced contract wins on both Tuesday and Thursday of this week is oil and gas engineering services business, Plexus, which has secured a £1m contract to supply its POS-GRIP technology well-head equipment to Lotos Exploration & Production Norge, a new customer for Plexus. The contract is for a two year period and can be extended for an additional year. Revenues are due to commence November 2012.

ValiRx, a life science company focused on cancer diagnostics, has entered into a UK distribution agreement with First Health Products for the distribution and sale of ValiRx's SELFCheck health screening products in the UK. The agreement, which is initially for a period of five years, means that the company will no longer incur any of the direct expenses or management time associated with the sales and marketing campaigns of SELFCheck products in the UK. ValiRx will continue to benefit from an income stream from the royalty payments made to the company from UK sales.

Speech recognition software specialist Eckoh has had its contract with cinema operator Vue Entertainment renewed for another three years. Eckoh supplies the technology which provides cinema listings information and ticket booking options over the phone. The contract, which runs until October 2015, has also made provision to include social media monitoring and broader customer interaction that will make additional use of Eckoh's multi-channel service capability.

JH

Recommended

Share tips of the week – 19 August
Share tips

Share tips of the week – 19 August

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
19 Aug 2022
How to invest in smart factories as the “fourth industrial revolution” arrives
Share tips

How to invest in smart factories as the “fourth industrial revolution” arrives

Exciting new technologies and trends are coming together to change the face of manufacturing. Matthew Partridge looks at the companies that will drive…
18 Aug 2022
How to invest today? Look to the past, not the future
Investment strategy

How to invest today? Look to the past, not the future

The past few years have seen so many changes to our way of life that many people said we had entered a “new normal”. But as it turns out, the new norm…
18 Aug 2022
A new legal headache for Haleon
Stocks and shares

A new legal headache for Haleon

Haleon, GSK’s former consumer-products arm, spun off last month, has made a dismal debut on the stockmarket.
17 Aug 2022

Most Popular

How to protect your wealth as inflation hits new record highs
Investment strategy

How to protect your wealth as inflation hits new record highs

UK inflation has hit a new record high of 10.1%. It's going to hurt, says Dominic Frisby. Here's how you can protect your wealth.
17 Aug 2022
How to cut your energy bill
Personal finance

How to cut your energy bill

The energy-price cap will almost double in the autumn. What does this mean for your money, and how can you alleviate the squeeze? Ruth Jackson-Kirby h…
17 Aug 2022
Are GSK’s legal troubles a threat to the firm’s survival?
Biotech stocks

Are GSK’s legal troubles a threat to the firm’s survival?

Pharmaceutical giant GlaxoSmithKline is facing legal action over heartburn drug Zantac that has seen billions wiped off its market value. Rupert Hargr…
16 Aug 2022